leisure time -WSS

leisure time

author：knowledge 2025-09-29 17:01:55 - browse：82449

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Neuroscience startup Neumora files for IPO

WSS

Psilocybin's anti

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Radiation, mainstay of cancer treatment, begins a fade

What do new weight loss drugs mean for bariatric surgery?

How to keep neuroscience’s past racism from being its future

How to make Best Hospitals ratings actually useful for patients

hotspot

leisure time

explore

Heart attack and stroke risk calculators need revising

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Malaria cases in Florida and Texas: Here’s what you need to know

Departing Stanford president retracts two papers

Hepatitis C has a cure — but many Americans still lack access to it

NYU Langone launches private ChatGPT for its health care data

As demand for Covid shots wanes, Moderna seeks its next success

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

The cancer drug shortage isn’t new — and neither are the solutions

Study finds new variant for Parkinson’s in African populations

hotspot

Virtual care provider acquires bankrupt Pear's prescription apps

Australia’s approach to dialysis celebrates life

Grail spinoff by Illumina should end disastrous merger attempt

Why health care costs have stayed mostly flat since 2010

Departing Stanford president retracts two papers

Study finds new variant for Parkinson’s in African populations

explore

leisure time

focus

leisure time